| [January 29, 2015] |
 |
Aurinia Pharmaceuticals to Present at the BIO CEO Investor Conference
Aurinia Pharmaceuticals, Inc., (NASDAQ: AUPH / TSX: AUP) today announced
that its President and Chief Executive Officer Stephen Zaruby will
present a corporate overview of the company at the BIO CEO Investor
Conference, taking place February 9th-10th in New York at the
Waldorf-Astoria Hotel. The presentation will also be available using the
webcast link below.
Aurinia Presentation Details
Date:
Tuesday, February 10th, 2015
Time: 3:00 p.m. Eastern
Standard Time
Location: Waldorf-Astoria Hotel
Webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2015/69221498302.cfm
About Aurinia
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com
for more information.
[ Back To TMCnet.com's Homepage ]
|
